Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

NCT05758116 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Consolidation Immunotherapy
Radiotherapy or Sequential Chemoradiation

Interventions

DRUG: Tislelizumab

Sponsor

Peking University Cancer Hospital & Institute